United States (Brussels Morning Newspaper) – Costco has started selling prescription weight-loss drugs Ozempic and Wegovy at its U.S. pharmacies for $499 per month, matching manufacturers’ discounted prices and offering additional savings for members. This move aims to improve accessibility amid the obesity epidemic and insurance coverage gaps.
Costco introduces Ozempic and Wegovy at discounted prices
Costco Wholesale Corporation announced on 6 October 2025 that it will offer popular weight-loss drugs Ozempic and Wegovy in its pharmacies across more than 600 U.S. locations. Dave Moore, executive VP of Novo Nordisk U.S. operations the Danish pharmaceutical company producing these drugs said the partnership helps make these FDA-approved medications more accessible and affordable where customers already shop.
The price for a one-month supply is $499, consistent with rates offered via Novo Nordisk’s direct-to-consumer platform, and at other major retailers such as CVS and Walmart. Costco executive members and Citibank Visa cardholders receive an additional 2% discount, providing further savings for customers purchasing without insurance.
Overview of Ozempic and Wegovy drugs
Ozempic (semaglutide) was originally developed to treat Type 2 diabetes by controlling blood sugar while also lowering risks of heart and kidney complications. Weight loss emerged as a beneficial side effect, leading to off-label use for obesity management. Wegovy, another semaglutide formulation, has full FDA approval specifically for chronic weight management, aiding appetite suppression and fat reduction in adults with obesity or overweight conditions.
While doctors prescribe both drugs with a requirement for a prescription, many insurers still do not fully cover their cost, making the $499 cash price at retailers like Costco significant for those paying out of pocket.
Market context and demand for weight-loss medications
Rising obesity rates across the United States have led to soaring demand for semaglutide-based therapies. However, market prices approaching $1,300 monthly for Wegovy and about $1,000 for Ozempic pose substantial barriers, as reflected in typical pharmacy retail prices outside discount programs. Novo Nordisk’s discount efforts aim to pre-empt competition from alternative weight-loss drugs such as Eli Lilly’s Mounjaro and Zepbound, as well as lower-cost compounding pharmacy versions.
Despite increased availability, experts note that less than half of employer-sponsored health insurance covers these drugs, underscoring the importance of accessible cash-pay options to enable broader patient use.
Costco’s role and benefits for customers
Offering these medications via Costco’s extensive pharmacy network provides convenience and cost savings for the company’s millions of members. Costco’s member prescription program includes added incentives like cash back for executive members and credit card holders, making Ozempic and Wegovy more financially accessible. Nevertheless, prescriptions from licensed healthcare providers remain mandatory to ensure safe appropriate use.
This collaboration reflects a broader trend where retail giants are becoming key players in pharmaceutical distribution, supporting public health with competitive pricing and wider reach.
Expert caution and medical advice
While Ozempic and Wegovy have demonstrated effectiveness in weight loss and improving metabolic health, medical professionals urge prospective users to consult with doctors thoroughly. These drugs require monitoring for side effects such as gastrointestinal issues, and are unsuitable for certain populations.
Experts also caution that medication should complement lifestyle changes like diet and exercise, not replace them. The surge in public interest has led to misinformation sometimes spread through telehealth platforms and unofficial sources, raising concerns over inappropriate use.
Future implications for obesity treatment
The rollout at Costco may signal increased mainstream acceptance and affordability of pharmacological interventions for obesity, potentially reshaping management of this global epidemic. As awareness grows, demand is likely to keep rising, which could spur further innovations and price competition in weight loss therapies.
Novo Nordisk’s strategy to improve supply chain accessibility through well-known retailers like Costco forms part of a wider attempt to tackle insurance coverage disparities and expand patient access.
Costco’s introduction of Ozempic and Wegovy at $499 a month stands to make these effective weight-loss drugs more attainable for many Americans, particularly those who lack insurance coverage. Though prescriptions are mandatory, the move represents a significant step towards affordable obesity treatment amidst a major public health challenge. The continuation of this trend depends on balancing accessibility, safety, and informed patient care.
Brussels Morning is a daily online newspaper based in Belgium. BM publishes unique and independent coverage on international and European affairs. With a Europe-wide perspective, BM covers policies and politics of the EU, significant Member State developments, and looks at the international agenda with a European perspective.
